1 week Ago By ABMN Staff
Legal & General Group Plc lifted its stake in Avadel Pharmaceuticals plc ( NASDAQ:AVDL – Free Report ) by 9.0% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 84,739 shares of the company’s stock after buying an additional 7,019 shares during the quarter.
Legal & General Group Plc owned about 0.09% of Avadel Pharmaceuticals worth $891,000 as of its most recent filing with the Securities & Exchange Commission. Other institutional investors have also recently made changes to their positions in the company.
Kazazian Asset Management LLC bought a new position in Avadel Pharmaceuticals in the 4th quarter worth approximately $126,000. Sanctuary Advisors LLC bought a new position in shares of Avadel Pharmaceuticals during the fourth quarter worth $140,000. Nations Financial Group Inc.
IA ADV bought a new position in shares of Avadel Pharmaceuticals during the fourth quarter worth $163,000. China Universal Asset Management Co. Ltd.
boosted its position in shares of Avadel Pharmaceuticals by 10.3% during the fourth quarter. China Universal Asset Management Co.
Ltd. now owns 20,432 shares of the company’s stock worth $215,000 after acquiring an additional 1,916 shares during the last quarter. Finally, KLP Kapitalforvaltning AS bought a new position in shares of Avadel Pharmaceuticals during the fourth quarter worth $218,000.
Institutional investors own 69.19% of the company’s stock. Wall Street Analyst Weigh In A number of equities analysts recently weighed in on the stock.
Deutsche Bank Aktiengesellschaft assumed coverage on shares of Avadel Pharmaceuticals in a research report on Tuesday, February 11th. They set a “buy” rating and a $12.00 target price for the company.
UBS Group dropped their target price on shares of Avadel Pharmaceuticals from $22.00 to $14.00 and set a “buy” rating for the company in a research report on Monday, January 13th.
Needham & Company LLC restated a “buy” rating and set a $19.00 target price on shares of Avadel Pharmaceuticals in a research report on Wednesday, April 9th. Piper Sandler lowered their price objective on shares of Avadel Pharmaceuticals from $24.
00 to $13.00 and set an “overweight” rating for the company in a research report on Friday, January 10th. Finally, HC Wainwright reissued a “buy” rating and issued a $21.
00 price objective on shares of Avadel Pharmaceuticals in a research note on Tuesday, March 4th. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $19.
88. Avadel Pharmaceuticals Trading Up 2.0 % Avadel Pharmaceuticals stock opened at $8.
77 on Monday. The firm has a 50-day moving average price of $7.93 and a 200-day moving average price of $9.
76. The firm has a market capitalization of $847.44 million, a PE ratio of -11.
10 and a beta of 1.52. Avadel Pharmaceuticals plc has a 12-month low of $6.
38 and a 12-month high of $19.09. Avadel Pharmaceuticals Company Profile ( Free Report ) Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States.
Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Read More Want to see what other hedge funds are holding AVDL? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Avadel Pharmaceuticals plc ( NASDAQ:AVDL – Free Report ). Receive News & Ratings for Avadel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avadel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter .
.
